QUEST DIAGNOSTICS INC
According to Digi Power X Inc.’s Aug. 14, 2026 SEC 10-Q, Q2 2026 revenue was $6.6M and net loss was $14.4M. The company said it is pivoting from crypto mining to AI data centers, secured major AI contracts, raised equity, and is seeking additional financing to expand data center capacity.
Quest Diagnostics (DGX) announced a quarterly cash dividend of $0.86 per share, payable Oct. 21, 2026, to shareholders of record Oct. 6, 2026. The stock was $236.04, down slightly over a week, with 30-day return 14.58% and YTD 35.82%. Simply Wall St estimates fair value at $245.87, citing dividend support and valuation assumptions, with risks including reimbursement and costs.
Digi Power X Inc. (DGX) reported in an Aug. 14, 2026 SEC 8-K that Q2 2026 included its first AI compute revenue, $1.1 billion in contracted AI data center revenue, and positive Adjusted EBITDA. The company cited a strong cash position, ongoing infrastructure investments, and 2027 revenue targets.
Over the past 7 days, alphai's AI scored 4 news stories mentioning DGX (QUEST DIAGNOSTICS INC). Coverage has skewed bullish: 2 bullish, 1 neutral, and 1 bearish.
Recent DGX coverage spans earnings, corporate actions and technology.
In the last 30 days, DGX insiders filed 1 SEC Form 4 transaction — no purchases and 1 sale ($376K). The most active reporter was DELANEY MARK E, SVP & Chief Commercial Officer, with 1 filing. 100% of those filings were made under pre-arranged Rule 10b5-1 plans.
The filing suggests a transition-phase burn rate while pursuing AI data-center contracts and additional financing.
The dividend declaration is a concrete capital-return update that can support income-focused demand, but the article provides no new earnings or guidance.
The filing suggests an inflection toward monetizing AI compute demand, with contracted revenue and profitability turning positive.
A declared dividend supports shareholder-return expectations but is typically not a major fundamental catalyst by itself.
Guidance lift supports bullish near-term sentiment, but the article flags reimbursement cuts and cost pressure as key margin risks.
alphai scores every news story that mentions DGX with an AI model for sentiment and relevance, and aggregates insider trades from QUEST DIAGNOSTICS INC's SEC EDGAR Form 4 filings. Figures refresh continuously.
According to Digi Power X Inc.’s Aug. 14, 2026 SEC 10-Q, Q2 2026 revenue was $6.6M and net loss was $14.4M. The company said it is pivoting from crypto mining to AI data centers, secured major AI contracts, raised equity, and is seeking additional financing to expand data center capacity.
1 min readQuest Diagnostics (DGX) announced a quarterly cash dividend of $0.86 per share, payable Oct. 21, 2026, to shareholders of record Oct. 6, 2026. The stock was $236.04, down slightly over a week, with 30-day return 14.58% and YTD 35.82%. Simply Wall St estimates fair value at $245.87, citing dividend support and valuation assumptions, with risks including reimbursement and costs.
6 min readDigi Power X Inc. (DGX) reported in an Aug. 14, 2026 SEC 8-K that Q2 2026 included its first AI compute revenue, $1.1 billion in contracted AI data center revenue, and positive Adjusted EBITDA. The company cited a strong cash position, ongoing infrastructure investments, and 2027 revenue targets.
1 min readQuest Diagnostics (NYSE:DGX) said its board declared a quarterly cash dividend of $0.86 per share. The dividend is payable Oct. 21, 2026, to shareholders of record as of Oct. 6, 2026, according to the company’s press release. The article notes DGX’s diagnostic services business.
1 min readQuest Diagnostics (DGX) reported 2Q and six-month 2026 results and raised full-year revenue and earnings guidance, according to the company. The article cites DGX shares up 8.34% (1 month), 23.58% (90 days), and 37.26% (1 year). It notes a fair value estimate of $239.38 versus a $233.72 close and flags reimbursement cuts and higher wage and automation costs as risks.
5 min readDaimini Chokshi Quest Diagnostics recruits Merck executive director Daimini Chokshi to serve as VP, investor relations, based at the company’s headquarters in Secaucus. During almost two decades at Merck, Chokshi held positions including director, investor relations and director, U.S. oncology finance.
2 min readQuest Diagnostics (NYSE: DGX) and Hologic, Inc. reported a Health Trends study using deidentified molecular lab data from 1.5 million women tested at Quest from 2022-2024. BV was found in 38.7% of cases; 12.0% of BV-positive women also had at least one STI versus 3.8% of BV-negative. BV-positive status showed higher odds of chlamydia, gonorrhea, and trichomonas.
3 min readQuest Diagnostics (NYSE: DGX) shares rose over 8% last week after the company raised its full-year outlook. In Q2, revenue increased 10% to $3 billion, with adjusted EPS up 19% to $3.12. Quest projects full-year revenue around $12 billion and adjusted EPS of $11.05 to $11.25, citing growth and margin gains from automation and AI.
4 min readMorgan Stanley raised its price target for Quest Diagnostics to $260 from $226 and kept an Overweight rating, according to the note cited by MT Newswires. The article also mentions Evercore ISI cutting its target to $240 from $225. Quest Diagnostics last closed at $227.90.
1 min readQuest Diagnostics (NYSE:DGX) reported Q2 CY2026 results. Revenue rose 10.2% year on year to $3.04 billion, exceeding Wall Street estimates by 2.3%. Non-GAAP adjusted EPS was $3.12, up from $2.62 and 10.5% above consensus. Analysts expect full-year revenue growth of 4.5% and EPS to rise from $10.64 to $11.17.
4 min read
